Construction of a genomic instability-derived predictive prognostic signature for non-small cell lung cancer patients

Non-small cell lung cancer (NSCLC) is the most common histologic subtype of lung cancer, accounting for over 80% of all cases[1,2]. The two common types of NSCLC are lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) [3]. Recently, monoclonal antibodies targeting the PD-1/PD-L1 axis have emerged as a primary treatment approach for advanced NSCLC [4]. However, despite the use of these antibodies, treatment outcomes remain suboptimal due to the development of drug resistance in a majority of patients.
Source: Cancer Genetics and Cytogenetics - Category: Genetics & Stem Cells Authors: Tags: Original Article Source Type: research